Shots:

• The P-III CLEAR study involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg- IV- q3w) or in combination with everolimus (5mg- qd) vs sunitinib (50 mg- q4w) in 1-069 patients for the 1L treatment with advanced RCC
• The trial met its 1EPs with Keytruda + Lenvima shows 61% reduction in the risk of disease progression or death- mPFS (2yrs. vs 9 mos.) 2 EPs shows 34% reduced the risk of death- ORR (71.0% vs 36.1%); CR (16.1 vs 4.2%); PR( 54.9% vs 31.9%); mDoR(25.8 vs 14.6mos)
• Lenvima + everolimus shows 35% reduction in the risk of disease progression or death; mPFS (14.7 vs 9.2mos); CR (9.8% vs 4.2%); PR (43.7% vs 36.1%); mDOR (16.6 vs 14.6 mos.)@median follow-up 27 mos.

 ­ Ref: Merck | Image: Merck